Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$9.65
-0.3%
$9.08
$6.23
$16.44
$2.12B0.932.92 million shs2.10 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$40.00
-7.3%
$53.90
$22.16
$60.08
$1.75B0.61323,920 shs976,061 shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$32.89
+0.3%
$34.34
$8.70
$40.22
$2.04B1.2488,114 shs693,127 shs
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
$29.00
+7.9%
$29.51
$14.39
$36.03
$506.45M3.27203,156 shs431,780 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.00%+3.31%+14.96%+5.68%+37.30%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%-18.84%-26.42%-18.67%+122.59%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
0.00%+0.21%-5.97%+1.20%+278.64%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
0.00%-3.93%-10.61%+10.26%+42.16%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$9.65
-0.3%
$9.08
$6.23
$16.44
$2.12B0.932.92 million shs2.10 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$40.00
-7.3%
$53.90
$22.16
$60.08
$1.75B0.61323,920 shs976,061 shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$32.89
+0.3%
$34.34
$8.70
$40.22
$2.04B1.2488,114 shs693,127 shs
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
$29.00
+7.9%
$29.51
$14.39
$36.03
$506.45M3.27203,156 shs431,780 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.00%+3.31%+14.96%+5.68%+37.30%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%-18.84%-26.42%-18.67%+122.59%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
0.00%+0.21%-5.97%+1.20%+278.64%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
0.00%-3.93%-10.61%+10.26%+42.16%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.79
Moderate Buy$23.78146.40% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.43
Hold$42.406.00% Upside
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
2.92
Moderate Buy$41.8327.19% Upside
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
2.88
Moderate Buy$80.57177.83% Upside

Current Analyst Ratings Breakdown

Latest TECX, PAHC, OCUL, and STOK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Reiterated RatingOutperform$30.00
5/5/2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Reiterated RatingBuy$18.00
4/21/2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Reiterated RatingSell (D-)
4/21/2026
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
Reiterated RatingSell (D-)
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageNeutral$62.00
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageHold$62.00
4/13/2026
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
Initiated CoverageBuy$75.00
4/13/2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Reiterated RatingBuy$21.00
4/10/2026
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Reiterated RatingHold (C)
3/20/2026
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Boost Price TargetBuy$36.00 ➝ $60.00
3/19/2026
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Reiterated RatingBuy$39.00
(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$51.95M40.67N/AN/A$2.66 per share3.63
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.25$3.03 per share13.20$8.93 per share4.48
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$184.42M11.11N/AN/A$6.17 per share5.33
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/AN/AN/AN/A$13.43 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3317.1712.200.666.35%37.14%8.57%6/30/2026 (Confirmed)
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$6.89M-$0.12N/AN/AN/A-529.20%-51.16%-43.78%N/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$74.15M-$4.46N/AN/AN/AN/A-31.20%-30.05%N/A

Latest TECX, PAHC, OCUL, and STOK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$0.80-$0.79+$0.01-$0.79$6.48 million$6.23 million
5/7/2026Q1 2026
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$1.16-$1.34-$0.18-$1.34N/AN/A
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
3/16/2026Q4 2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A-$0.97N/A-$0.97N/A$1.40 million
2/26/2026Q4 2025
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$1.11-$1.03+$0.08-$1.03N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.20%N/A20.60%N/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/AN/AN/AN/AN/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/AN/AN/AN/AN/A

Latest TECX, PAHC, OCUL, and STOK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.120.85%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.12
14.81
15.32
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.22
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
5.28
5.28
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/A
26.62
26.63

Institutional Ownership

CompanyInstitutional Ownership
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
59.21%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
62.63%

Insider Ownership

CompanyInsider Ownership
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.30%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.13%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
9.50%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
39.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
230218.96 million213.92 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.53 million20.22 millionOptionable
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
10062.27 million56.36 millionOptionable
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
12018.85 million11.35 millionN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ocular Therapeutix stock logo

Ocular Therapeutix NASDAQ:OCUL

$9.65 -0.03 (-0.31%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$9.44 -0.22 (-2.23%)
As of 05/8/2026 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$40.00 -3.16 (-7.32%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$41.08 +1.08 (+2.70%)
As of 05/8/2026 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Stoke Therapeutics stock logo

Stoke Therapeutics NASDAQ:STOK

$32.89 +0.10 (+0.30%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$31.72 -1.17 (-3.55%)
As of 05/8/2026 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Tectonic Therapeutic stock logo

Tectonic Therapeutic NASDAQ:TECX

$29.00 +2.13 (+7.93%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$30.74 +1.74 (+6.00%)
As of 05/8/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.